Your fact-checks will appear here
World Health Organization drug safety database
Ivermectin in adults is associated with a spectrum of recognized adverse reactions that can be neurological (confusion, seizures, encephalopathy) and allergic or cutaneous (rash, pruritus, severe hype...
Drug‑induced liver injury (DILI) from ivermectin in humans is , primarily in case reports and pharmacovigilance datasets rather than large prospective studies. Available evidence shows occasional seri...
Available reports show ivermectin is usually well tolerated at standard single-dose regimens but has documented, rare cases of clinically apparent liver injury and even fulminant liver failure after n...
Fixed‑dose ivermectin has been evaluated in a mix of individual‑level meta‑analyses, operational trials, and cohort safety surveillance that together show broadly low rates of common adverse events in...
Off‑label and veterinary use of during the COVID‑19 pandemic produced a measurable uptick in reported adverse events and produced clearer “signals,” driven largely by misuse, overdosing and ingestion ...
Case series, pharmacovigilance data and isolated case reports describe ivermectin‑associated hepatic injury ranging from asymptomatic transaminase elevations to fulminant hepatitis; most published sig...
Serious adverse reactions reported with ivermectin include neurologic events (encephalopathy, confusion, coma), severe cutaneous reactions (Stevens–Johnson syndrome, toxic epidermal necrolysis, DRESS)...
There are no single, global "official guidelines" that specifically prescribe ivermectin use in people with chronic liver disease; major drug references and pharmacovigilance reports advise caution an...